PSI reaches into Austria; Almac inks a $365M Roche deal;

> Swiss CRO PSI has opened a new outpost in Vienna, part of a sweeping effort to expand across Europe. More

> Almac's drug discovery operation has inked a deal with Roche's ($RHHBY) Genentech, out-licensing a cancer program for $14.5 million up front and as much as $349 million in milestones. News

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.